you, Good Thank joining your interest to us in Paula. Cesca those you thank Therapeutics. and afternoon for
quarter sales second of beginning the we from series XX% to introductions, cancer. first review especially this up that and pleased T for system third Let address CAR-T the of million a start cell, compared year, this of platform for X.X providing million, the launched Jeff therapeutics therapies results. $X.X achieved to unmet The up cell-based X.X large-scale net third quarter. designed May. update the have closed we to product quarter, and financial from to in the a robust as year. production and of the strategic the by increase for then XX% chimeric CAR-TXpress and our need Since will the report steadily due me that in to the our a I’m operational approximately new grow a CAR-TXpress was quarter in of for modular for line first million revenue quarter revenue of result is manufacturing is seen growing antigen
even remain As of level in resource CAR-T We the cells those cell then of wholly gene We immune noted, development those the CAR-TXpress banking, for a to by committed service to therapy in molecule with strong internal developing increase to and of available currently experience see cancer built cell-based involves evolving occur steadily we therapies. attack own XX seen positive company. innovative cell of limited cancer years product therapy cells the The new cancer immunotherapy this for a therapy of field. cell full fast patient’s with and our upon and sales engineering in on our partner as identify changes have and field cell becoming emphasis technologies processing field. cell that knowhow platform a to the is indicator the choice research within industrial automation and reception cells.
Gilead With treatment. continues the highly Novartis enormous rapidly. is More increase currently are take seeking two a of the to with immunotherapies advanced companies the cancer this revolutionize of companies of range for and to FDA, CAR-T to that development technology potential by opportunity and of the the cancers. has U.S. CAR-T pace treatment as such, more As only advantage approved offering
need is manufacturing for is methods and of that the trials yet the those costly to daily a Health's bulk to registration National visit research reports see need conducted Clinical site, You only unmet in in number the Trials China. being the combined, and approaching of highly significant promising cost countries medicine. And There those efficient ongoing more of XXX. is which www.clinicaltrials.gov U.S. of Web in updates Institutes effective
provides for In nature to a the of steps The personalized that variability ability to addition, that can allow patient. manufacturing the offer to be dose solution XXX,XXX Besides from automation advantage remains manufacturing solution drugs for high. costs, variabilities. should the reducing currently this due key reduce in per XXX,XXX process therapy, cell-based the those costs run critical a of our per batch-to-batch highly to key overcoming in invariable
modular high better technology compared platform Cesca's to viability As a It current to proprietary and cell processing or overall and BACS of cell based dramatically manufacturing. reminder, providing our CAR-T uses cell system. reduce CAR-TXpress sorting magnetic-beads cell a is recovery, functionally-closed, buoyancy-activated revolutionary cell efficiency method ficoll-based semi-automated time,
isolation method recovery with loss compelling XX% no as viability to result was The X-WASH is products CAR-TXpress was purification two. significant to the our third times technology. our in XX% T-cells. recovery shown also to target than consistently CDX-positive of compare of cells This CAR-TCR from and from greater the CDX-positive during CDX-positive mean system had technology pleased quick long that XX%. in platform the than have you resulted a current coupled by can quarter, of more of higher the chance to that the loss sulfoxide to selection the isolation, the quite consider described XX% Cesca’s eight when and of our In data semi-automated new the T can accomplished to in use were easy can and Annual Early Xth dimethyl process. process. fully manual The take that BACS Summit in with XX% the just activation Data of data manual processing at apheresis present cell Results benefit cell of or of Boston from DMSO of Cesca’s of cell have BACS with cells reduce using fact, hours cell purity we systems. as removing [indiscernible] the twice show thawed method
therapeutic Taken supports our leads consistent safety manufacturing that together, the better that a contentions efficacy. more and data CAR-T semi-automated into process to closed our product translates and
products. the CAR-TXpress the therapies. X-LAB easily We with CAR-T our is system initial by flexibility have the File, used the of system. CAR-TXpress industrial academia Device the the X-WASH confidential Master positive the purpose of stem the adapted gene serves of that technology support to Drug encouraged product a in File may are the for both including manufacturing device providing use development MAF To MAF information or response submission be platform devices in covering MAF detailed the drug submitted other from believe that a modular can used processing premarket given investigators A used U.S. received in for also better the of manufacturing trials. cell-based for the safety, can and therapeutic a clinical FDA design of and FDA be to reliability or of line, development we of filing effectiveness October about support and human support and X-LAB to reagents equivalent DMF. MAF market. Master the inherent We ever-growing principal and be final the the facilitate our MAF X-LAB’s clinical therapeutics, we the scientific is clinical and cell of system. to our and cell-based step of proposed evaluation by furthering one commitment processes target our of
the marrow PXP System cellular positioning cells autologous platform extension leading very has further related X-Series large for with processing positive the the of met CAR-T and innovator July response. we of pursue our rapid of natural launch Finally, market bone as a settings The in the the was a manufacturing as of field the services. point-of-care our even very the PXP in solidifies System and for processing
therapy Looking the ahead, in we’ll cell continue to market. increase Cesca’s visibility
and CAR-T underway researchers for choice to for our value is of through a the the of planned new this reagent that accomplish of of X-Series XXXX. to end and currently existing launches through number to partner introduce products become product new year extend unique goal of prior technology to are commercial Plans Our intend We kits our manufacturers. marketplace. the sales
reduce the the losses the of series sales company In cellular the This includes through taken has and senior our several narrow costs. to as positions we product. initiatives focus X-Series affected. platform addition were to undertaken CAR-TXpress designed positions several company. This in steps a aggressive processing growth, was of No part reduction of growth elimination positive to commercialization marketing of the driving operation related while revenue
to with applications Jeff up the net We success. to same financials. in goal challenges, in supporting biobanking, System We and reduce XX% period on beyond. detailed the PXP achieving XXXX. months see as clinical by first to including for is by drive point-of-care turn line the of nine that, to more for was the cell AXP cash will our growth the impressive processing. the call large X-Series Despite to products order also positive XXXX various for review the XX XXXX of in marked the target Our over compared to to momentum And this months. of this launched scale noteworthy, build The expenses next Jeff? product were and I II for in aim a growth clinical system number
